Dr John Burt Checton, MD in Eatontown, NJ - Medicare

Dr John Burt Checton, MD is a medicare enrolled "Nuclear Medicine - Nuclear Imaging & Therapy" physician in Eatontown, New Jersey. His current practice location is 11 Meridian Rd, Eatontown, New Jersey. You can reach out to his office (for appointments etc.) via phone at (732) 663-0300.

Dr John Burt Checton is licensed to practice in New Jersey (license number 25MA03632000) and he also participates in the medicare program. He accepts medicare assignments (which means he accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and his NPI Number is 1962476416.

Contact Information

	Dr John Burt Checton, MD
	11 Meridian Rd, Eatontown, NJ 07724
	(732) 663-0300
	(732) 663-0301

Physician's Profile

Full Name	Dr John Burt Checton
Gender	Male
Speciality
Experience	Years
Location	11 Meridian Rd, Eatontown, New Jersey
Accepts Medicare Assignments	Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.

Medical Education and Training:

Dr John Burt Checton attended and graduated from in

NPI Data:

NPI Number: 1962476416
Provider Enumeration Date: 02/13/2006
Last Update Date: 07/02/2019

Medicare PECOS Information:

PECOS PAC ID:
Enrollment ID:

Medical Identifiers

Medical identifiers for Dr John Burt Checton such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1962476416	NPI	-	NPPES
2320002	Medicaid	NJ

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207RC0000X	Internal Medicine - Cardiovascular Disease	MA36320 (New Jersey)	Secondary
207UN0902X	Nuclear Medicine - Nuclear Imaging & Therapy	25MA03632000 (New Jersey)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr John Burt Checton is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr John Burt Checton, MD 11 Meridian Rd, Eatontown, NJ 07724-2242 Ph: (732) 663-0300	Dr John Burt Checton, MD 11 Meridian Rd, Eatontown, NJ 07724 Ph: (732) 663-0300

News Archive

Recipients of the second round of funding under CLL/SLL Research Initiative announced by LRF

The Lymphoma Research Foundation (LRF) is pleased to announce that David Frank, MD, PhD of the Dana-Farber Cancer Institute and Thomas Kipps, MD, PhD, Moores Cancer Center, University of California, San Diego are the recipients of the second round of funding under the Foundation's Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Research Initiative.

The Automation Partnership announces the US launch of Cell-IQ

The Automation Partnership (TAP), a world leader in the design and development of innovative automation for life science applications, today announced the US launch of Cell-IQ® - a live cell observation and analysis system.

Researchers pinpoint mechanism underlying astrocyte-mediated recovery of brain tissue after injury

A Kobe University research team has pinpointed the mechanism underlying astrocyte-mediated restoration of brain tissue after an injury. This could lead to new treatments that encourage regeneration by limiting damage to neurons incurred by reduced blood supply or trauma.

Remnant fetal tissue could contribute to enlarged prostate in later life

New research from Michigan State University indicates that embryonic tissue, key to the development of a baby's gender, could contribute to an enlarged prostate, or BPH, in men later in life.

AstraZeneca/Targacept's TC-5214 for treatment resistant depression to earn Decision Resources' gold standard status

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for treatment resistant depression therapy, AstraZeneca/Targacept's TC-5214 will earn Decision Resources' proprietary clinical gold standard status in 2013 (following its approval that year) and through 2018.

Dr John Burt Checton, MD - Medicare in Eatontown, NJ